Validant Group of Companies Unite as ELIQUENT Life Sciences
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
WASHINGTON -- Businesswire -- The Validant Group of companies today announced a strategic repositioning that unites the five companies as one global regulatory brand: ELIQUENT Life Sciences.
ELIQUENT Life Sciences is the fusion of five global regulatory consultancies: Validant (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.validant.com%2F&esheet=53878366&newsitemid=20240108602624&lan=en-US&anchor=Validant&index=1&md5=f9284bfc04faeff28b71547328c6a18d), Greenleaf Health (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.greenleafhealth.com%2F&esheet=53878366&newsitemid=20240108602624&lan=en-US&anchor=Greenleaf+Health&index=2&md5=ef3ad5581850e87892a4893acfd69c8c), DataRevive (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.data-revive.com%2F&esheet=53878366&newsitemid=20240108602624&lan=en-US&anchor=DataRevive&index=3&md5=d8670b49f062012658efaa0d5e3bbd22), Oriel Stat-a-Matrix (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.orielstat.com%2F&esheet=53878366&newsitemid=20240108602624&lan=en-US&anchor=Oriel+Stat-a-Matrix&index=4&md5=37861e8f55ae2719a7b3d8c222705ac2), and IDEC (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.idec-inc.com%2F&esheet=53878366&newsitemid=20240108602624&lan=en-US&anchor=IDEC&index=5&md5=d1db9b05f8da5c8004e6b12af9120f60). The collective capabilities of this unmatched alliance enable integrated solutions that bridge the spectrum of regulatory challenges. ELIQUENT Life Sciences delivers comprehensive services that support pharmaceutical, biotechnology, and medical device companies navigating the complex regulatory landscape.
“ELIQUENT Life Sciences is an unprecedented assembly of regulatory leaders, industry experts, and technical specialists. Our combined capabilities deliver the best path forward for global life science innovators. Together, ELIQUENT sets a new standard for regulatory excellence,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences.
Full-Service Engagement
The ELIQUENT team works cross-functionally to deliver solutions that global life science innovators need to gain and maintain authorization for the products. Guided by decades of regulatory and clinical experience, ELIQUENT’s team of life science experts have the specialized skills to assist clients across therapeutic modalities, phase-based pathways, and major global markets.
The combined achievements and substantial qualifications of the ELIQUENT team enable a full-service engagement that delivers end-to-end support in the following areas:
Regulatory Affairs Solutions From the earliest phases of development, through regulatory submissions, to post-approval support, ELIQUENT’s robust blend of technical skill and clinical expertise guide companies to approval and beyond.
Pharmacovigilance & Post-Market Surveillance Solutions With an approach that includes both strategic direction and hands-on global support, ELIQUENT’s customized pharmacovigilance services empower companies to operate with confidence.
Quality & Compliance Solutions ELIQUENT’s highly specialized compliance experts build customized solutions that equip companies with best-in-class strategic support, technical guidance, and project-based achievements.
Remediation Solutions ELIQUENT’s team of respected professionals, along with a network of ready to deploy global experts, bring an unrivaled level of credibility and trust when interacting with regulators and guiding companies to remediation success.
Expert Training ELIQUENT’s customizable training programs provide in-person and remote training services to empower both leadership teams and employees with the skills and tools to create pragmatic problem-solving processes and maintain adherence to evolving regulatory, compliance, and quality standards.
The strategic repositioning of ELIQUENT Life Sciences is supported by GHO Capital, the European specialist investor in healthcare. Having partnered with Validant since December 2018, today’s announcement follows the acquisition of DataRevive in 2019, a regulatory strategy and consultancy for global clients; November 2020 acquisition of IDEC, a leading regulatory consultancy in Japan; December 2020 acquisition of Oriel STAT A MATRIX, a global consultancy and training firm for the medical device industry; and April 2021 acquisition of Greenleaf Health, a leading FDA regulatory consulting firm.
About GHO Capital
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240108602624/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:ELIQUENT Life Sciences
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 일렉트로닉 월드 뮤직 듀오 애니멀다이버스, 두번째 정규 앨범 ‘Odyssey’ 발매 - 뉴스와이어
- 한국디지털광고협회 ‘2024년 대한민국 디지털 광고 대상’ 개최 - 뉴스와이어
- 아이지, 반도체 플라즈마 응용 실습 장비 개발… 공급 본격화 - 뉴스와이어
- 국립나주병원, 직장인 정신건강 심포지엄 개최 - 뉴스와이어
- 사랑의달팽이, 우리금융미래재단과 함께 청각장애인 101명에 소리 선물 - 뉴스와이어
- 원텍, 중국 SBT와 합작법인 설립 계약 체결 - 뉴스와이어
- NI의 새로운 USB C타입 DAQ 4종 출시… 더 많은 엔지니어들에게 품질 인사이트 제공 - 뉴스와이어
- 어떤 망한 요리도 새미네부엌에서 다 살려드려요… 샘표, 요리 즐거움 알리는 ‘망한 요리 인증
- 에쓰-오일토탈에너지스윤활유, 쿼츠 엔진오일 신규 광고 공개 - 뉴스와이어
- KPR 디지털커뮤니케이션연구소, 빅데이터 분석 통해 고물가 시대 소비 트렌드 분석 결과 발표 -